Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adjusting D-dimer to Lung Disease Extent to Exclude Pulmonary Embolism in COVID-19 Patients (Co-LEAD).
Planquette B, Khider L, Berre AL, Soudet S, Pernod G, Mao RL, Besutti M, Gendron N, Yanoutsos A, Smadja DM, Goudot G, Kahf SA, Mohamedi N, Hamoud AA, Philippe A, Fournier L, Rance B, Diehl JL, Mirault T, Messas E, Emmerich J, Chocron R, Couturaud F, Ferretti G, Sevestre MA, Meneveau N, Chatellier G, Sanchez O. Planquette B, et al. Among authors: besutti m. Thromb Haemost. 2022 Nov;122(11):1888-1898. doi: 10.1055/a-1768-4371. Epub 2022 Feb 10. Thromb Haemost. 2022. PMID: 35144305 Free PMC article.
Elevated D-dimers and lack of anticoagulation predict PE in severe COVID-19 patients.
Mouhat B, Besutti M, Bouiller K, Grillet F, Monnin C, Ecarnot F, Behr J, Capellier G, Soumagne T, Pili-Floury S, Besch G, Mourey G, Lepiller Q, Chirouze C, Schiele F, Chopard R, Meneveau N. Mouhat B, et al. Among authors: besutti m. Eur Respir J. 2020 Oct 22;56(4):2001811. doi: 10.1183/13993003.01811-2020. Print 2020 Oct. Eur Respir J. 2020. PMID: 32907890 Free PMC article.
Effect of weight-adjusted intermediate-dose versus fixed-dose prophylactic anticoagulation with low-molecular-weight heparin on venous thromboembolism among noncritically and critically ill patients with COVID-19: the COVI-DOSE trial, a multicenter, randomised, open-label, phase 4 trial.
Zuily S, Lefèvre B, Sanchez O, Empis de Vendin O, de Ciancio G, Arlet JB, Khider L, Terriat B, Greigert H, Robert CS, Louis G, Trinh-Duc A, Rispal P, Accassat S, Thiery G, Montani D, Azarian R, Meneveau N, Soudet S, Le Mao R, Maurier F, Le Moing V, Quéré I, Yelnik CM, Lefebvre N, Martinot M, Delrue M, Benhamou Y, Parent F, Roy PM, Presles E, Goehringer F, Mismetti P, Bertoletti L, Rossignol P, Couturaud F, Wahl D, Thilly N, Laporte S; COVI-DOSE investigators. Zuily S, et al. EClinicalMedicine. 2023 Jun;60:102031. doi: 10.1016/j.eclinm.2023.102031. Epub 2023 Jun 9. EClinicalMedicine. 2023. PMID: 37350990 Free PMC article.
[No title available]
Besutti M, Schiele F. Besutti M, et al. Rev Prat. 2024 Mar;74(3):255. Rev Prat. 2024. PMID: 38551860 French. No abstract available.
OPTImized coronary interventions eXplaIn the bEst cliNical outcomEs (OPTI-XIENCE) study. Rationale and study design.
Moreno R, Baptista SB, Valencia J, Gomez-Menchero A, Bouisset F, Ruiz-Arroyo JR, Bento A, Besutti M, Jimenez-Valero S, Rivero-Santana B, Olhmann P, Santos M, Vaquerizo B, Cuissetm T, Lemoine J, Pinar E, Fiarresga A, Urbano C, Marliere S, Braga C, Amat-Santos I, Morgado G, Sarnago F, Telleria M, Van Belle E, Díaz-Fernandez J, Borrego JC, Amabile N, Meneveau N. Moreno R, et al. Among authors: besutti m. Cardiovasc Revasc Med. 2024 Feb;59:93-98. doi: 10.1016/j.carrev.2023.08.011. Epub 2023 Sep 4. Cardiovasc Revasc Med. 2024. PMID: 37723011
12 results